Search
Search Results
-
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025 - Focus on prevention and treatment of cardiometabolic disease
2521PDF: 3007Supplementary: 359Appendix: 295 -
Lipoprotein(a): what clinicians need to know
620PDF: 1009HTML: 32 -
The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta-analysis
2879PDF: 710Conflict of interest: 337SUPPLEMENTARY MATERIAL: 283HTML: 83 -
Sex differences in clinical characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction
876PDF: 236Supplementary: 170Appendix: 123HTML: 56 -
Sex-based differences in characteristics, management, and outcomes in heart failure with reduced ejection fraction
895PDF: 275Supplementary: 167Appendix: 123HTML: 77 -
Modulation of cardiac metabolism in heart failure
2464PDF: 1204HTML: 61 -
The association of iron deficiency with right ventricular dysfunction in Africans with heart failure
2511PDF: 426Appendix B: 467Appendix A: 332HTML: 6 -
The impact of frailty on in-hospital outcomes in patients with HFrEF
375PDF: 138Supplementary: 35HTML: 16 -
Coronary artery calcium scoring. What clinicians need to know
1499PDF: 455HTML: 177 -
Is the obesity paradox present in left ventricular assist device recipients? A BMI-based analysis
274PDF: 295Supplementary: 160HTML: 37 -
SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials
1305pdf: 298Supplementary Material: 50HTML: 162 -
-
Evolving targets for heart failure: the journey so far
2164pdf: 384HTML: 4 -
Treatment pathways in patients with heart failure with preserved ejection fraction and obesity: perspectives from cardiology specialists and patients
2131PDF: 577SUPPLEMENTARY MATERIAL: 324GRAPHICAL ABSTRACT: 281HTML: 44

